BioArctic awarded patent by EPO for potential Alzheimer's antibodies

By The Science Advisory Board staff writers

The European Patent Office (EPO) has granted Swedish-based biopharmaceutical company BioArctic patent EP 2, 558, 968 B1 for its novel antibodies that could be developed to treat Alzheimer's disease.

The antibodies target a truncated form of amyloid beta (pE3-Aβ) and are part of BioArctic's AD1503 program. Monomers of pE3-Aβ are highly prone to aggregate, leading to the formation of harmful amyloid beta aggregates, which cause the symptoms associated with Alzheimer's disease. The company believes that focusing on other forms of amyloid beta species in the Alzheimer's disease cascade can open the door for future treatment possibilities.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking